US OptionsDetailed Quotes
OCGN241220P2000
- 0.92
- 0.000.00%
15min DelayClose Nov 25 16:00 ET
0.00High0.00Low
0.92Open0.92Pre Close0 Volume1 Open Interest2.00Strike Price0.00Turnover212.24%IV-17.14%PremiumDec 20, 2024Expiry Date1.08Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8726Delta0.4279Gamma0.84Leverage Ratio-0.0020Theta-0.0009Rho-0.73Eff Leverage0.0005Vega
Ocugen Stock Discussion
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease
Ocugen Announces Compelling Preliminary Data for Ocu410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
No comment yet